Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
The Company's common stock is expected to start trading on a split-adjusted basis on August 18, 2025.
Reason for Reverse Split
To comply with the minimum bid price requirement for Nasdaq listing.
Impact on Outstanding Shares
Reduction from approximately 4.77 million shares to 1.59 million shares.
Fractional Shares
Stockholders entitled to cash instead of fractional shares.
- The reverse stock split reflects the Company's strategic move to meet Nasdaq requirements.
- Reducing outstanding shares can influence the stock's market perception and liquidity.
The reverse stock split by Entero Therapeutics, Inc. showcases efforts to enhance shareholder value and maintain Nasdaq market listing.